Drug Price Trends for BYSTOLIC

Average Pharmacy Cost for BYSTOLIC

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
BYSTOLIC 5 MG TABLET	00456-1405-90	6.43136	EACH	2026-01-02
BYSTOLIC 20 MG TABLET	00456-1420-90	6.42428	EACH	2026-01-02
BYSTOLIC 10 MG TABLET	00456-1410-90	6.43448	EACH	2026-01-02
BYSTOLIC 2.5 MG TABLET	00456-1402-30	6.43806	EACH	2026-01-02

Market Analysis and Price Projections for Bystolic (Nebivolol)

Last updated: February 14, 2026

Market Overview

Bystolic (nebivolol) is a beta-1 adrenergic receptor blocker approved by the FDA in 2012 for hypertension and heart failure management. Manufactured by Allergan (acquired by AbbVie in 2020), it competes primarily with other beta-blockers such as metoprolol, atenolol, and bisoprolol.

Market Size and Trends

The global antihypertensive drugs market was valued at approximately $22 billion in 2022, with beta-blockers accounting for 15% (around $3.3 billion). Bystolic holds an estimated 20–25% share within the beta-blocker segment, equating to roughly $0.66–0.83 billion in global sales (2022).

Sales peaked at $720 million in 2017 but declined to about $550 million in 2022 due to generic competition. Generics entered the market around 2018–2019, eroding premium pricing and market share for the brand-name drug.

Competitive Landscape

Generic nebivolol prescriptions increased significantly post-patent expiry in 2019. As of 2023, generic versions account for over 70% of nebivolol prescriptions in the US, with branded Bystolic representing less than 30%.

Other beta-blockers with established brand presence, such as Lopressor (metoprolol tartrate), maintain larger market shares because of broader indications, extensive clinician familiarity, and established dosing protocols.

Pricing Dynamics

• Brand Bystolic: Prescribed at approximately $530–$650 for a 30-day supply (30 tablets of 10 mg).

• Generic Nebivolol: Retail prices range from $10–$20 for a 30-day supply, reflecting significant price erosion post-generic entry.

Insurance coverage and PBM (pharmacy benefit manager) negotiations heavily influence out-of-pocket costs, with patients often paying minimal copays for generics.

Price Projections

Considering current trends, the following projections are relevant:

Scenario	Year	Estimated US Brand Price	Estimated US Generic Price	Remarks
Conservative	2025	$400–$500	$10–$15	Stable generic dominance; slight brand price decline due to market saturation.
Moderate	2025	$350–$450	$10	Increased generic market share; potential for slight brand price reductions.
Optimistic	2025	$300–$350	$8–$10	Increased differentiation or formulary restrictions favoring branded sales.

Worldwide pricing trends mirror US declines, influenced by healthcare policies, formulary changes, and generic proliferation.

Regulatory Landscape

Bystolic's patent protection expired in 2018 in the US, prompting generic manufacturers to enter the market. No significant patent litigations or exclusivity extensions are currently active.

AbbVie's focus has shifted toward newer therapeutics, reducing emphasis on Bystolic. The drug's positioning relies largely on prescriber familiarity and insurance formularies.

Future Market Dynamics

• Generic Market Growth: Expected to account for over 85% of nebivolol prescriptions by 2025.
• Pricing Pressure: Stable downward pressure persists due to increased generics.
• Potential New Indications: Limited, given current labeling.
• Biosimilars/Alternative Therapies: Not applicable; small-molecule beta-blockers have no biosimilar equivalents.

Sales and Market Entry Barriers

Barriers include clinician familiarity with multiple beta-blockers, cost sensitivity, and formulary restrictions favoring generics over branded products.

Market entry of new, innovative antihypertensives or non-beta-adrenergic therapies could further diminish Bystolic's relevance.

Summary

The Bystolic market has contracted since 2018 due to patent expiration and generic competition. Prices for brand-name Bystolic are projected to decrease further, stabilizing around $300–$450 in the US by 2025. Generics will dominate sales, priced around $8–$15.

Key Takeaways

• Bystolic's peak US sales reached approximately $720 million in 2017 before declining sharply post-generic entry.
• Current US brand pricing ranges from $530–$650; generics are around $10–$20.
• Market share for the brand has diminished to less than 30%; generics dominate.
• Price projections for 2025 estimate $350–$450 for branded Bystolic and $8–$15 for generics.
• Future growth prospects depend on market share retention, formulary policies, and competition from newer antihypertensives.

FAQs

1. What is the primary driver for the decline in Bystolic sales?
   Patent expiration and the rapid uptake of generics caused significant price erosion and market share decline.

2. Are there any emerging indications for Bystolic?
   No significant new indications are currently in development; the drug is mainly used for hypertension and heart failure.

3. How do insurance formularies impact Bystolic’s market share?
   Formularies favor generics due to lower costs, reducing prescriptions of branded Bystolic.

4. Can Bystolic regain market share?
   Unlikely unless a new formulation or indication provides a competitive advantage or prescriber preference shifts.

5. What is the long-term outlook for Bystolic pricing?
   Prices are expected to decline further, stabilizing around $300–$450 for the brand and below $10 for generics by 2025.

---

Sources

[1] IQVIA RxPulse, 2022.
[2] GoodRx Price Comparison, 2023.
[3] FDA Patent Data, 2018.
[4] MarketResearch.com, 2022.
[5] EvaluatePharma, 2022.